October 22, 2007
Anesiva issued positive results from a phase III trial of Zingo for the treatment of pain associated with venous access procedures in adults. This randomized, double-blind study enrolled 699 adult subjects in the US. The subjects were treated with Zingo or placebo one to three minutes prior to undergoing intravenous cannulation or venipuncture. The primary endpoint was pain upon needle insertion utilizing the Visual Analog Scale (VAS) for pain. The mean pain score in the Zingo-treated group was significantly lower than in the placebo group (p = 0.003). Based on the results, Anesiva plans to file a sNDA with the FDA in early 2008.